Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 7 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.7% | +31.8% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
| BROWE, DAVID | 1 | 26.4% | +27.3% |
| ROSEBACH, CHRISTINA H.W. | 1 | 59.2% | -35.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17277019 | Functionalized Surface | ROSEBACH, CHRISTINA H.W. | 153d overdue |
| 18012561 | MMP-9 AND MMP-12 INHIBITION FOR TREATING SPINAL CORD INJURY OR RELATED INJURY TO NEUROLOGICAL TISSUE | SAMSELL, RILLA MARIE | 8d overdue |
| 18838225 | GENERATING BONE MARROW ORGANOIDS | BERKE-SCHLESSEL, DAVID W | — |
| 18517633 | T CELL ACTIVATION | HOWARD, ZACHARY C | — |
| 18488234 | BONE DISEASE TREATMENT | ESPINOSA, CLAUDIA EDILMA | — |
| 18269308 | NANOBODY TO GLYCOPROTEIN VI | REDDIG, PETER J | — |
| 17311534 | THERAPEUTIC HYDROGEL COMPOSITIONS | BROWE, DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838225 | GENERATING BONE MARROW ORGANOIDS | BERKE-SCHLESSEL, DAVID W | — |
| 18517633 | T CELL ACTIVATION | HOWARD, ZACHARY C | — |
| 18488234 | BONE DISEASE TREATMENT | ESPINOSA, CLAUDIA EDILMA | — |
| 18269308 | NANOBODY TO GLYCOPROTEIN VI | REDDIG, PETER J | — |
| 17311534 | THERAPEUTIC HYDROGEL COMPOSITIONS | BROWE, DAVID | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1646 | 1 |
| 1624 | 1 |
| 1617 | 1 |
| 1766 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838225 | GENERATING BONE MARROW ORGANOIDS | BERKE-SCHLESSEL, DAVID W | — | §102§103 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18517633 | T CELL ACTIVATION | HOWARD, ZACHARY C | — | §102§112 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18488234 | BONE DISEASE TREATMENT | ESPINOSA, CLAUDIA EDILMA | 1654 | §102§112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18269308 | NANOBODY TO GLYCOPROTEIN VI | REDDIG, PETER J | 1646 | §102§112 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 18012561 | MMP-9 AND MMP-12 INHIBITION FOR TREATING SPINAL CORD INJURY OR RELATED INJURY TO NEUROLOGICAL TISSUE | SAMSELL, RILLA MARIE | 1624 | §103§112 | Final Rejection | 8d overdue | Pending | Dec 22, 2022 |
| 17311534 | THERAPEUTIC HYDROGEL COMPOSITIONS | BROWE, DAVID | 1617 | §103§112 | Non-Final OA | — | Pending | Jun 07, 2021 |
| 17277019 | Functionalized Surface | ROSEBACH, CHRISTINA H.W. | 1766 | §103§112 | Non-Final OA | 153d overdue | Pending | Mar 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial